Volume 38 Issue 5
May  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Nanjing University of traditional Chinese Medicine  > 2022  >  38(5): 397-403
ZHOU Min, SHEN Shu-hua, CHENG Ye, LI Wei-bing, YU Ya-su, CHEN Yan. Clinical Observation of Gegen Qinlian Decoction for Post-TACE Embolization Syndrome in Hepatocellular Carcinoma Patients with the Syndrome of Damp-Heat and Stasis-Toxin[J]. Journal of Nanjing University of traditional Chinese Medicine, 2022, 38(5): 397-403. doi: 10.14148/j.issn.1672-0482.2022.0397
Citation: ZHOU Min, SHEN Shu-hua, CHENG Ye, LI Wei-bing, YU Ya-su, CHEN Yan. Clinical Observation of Gegen Qinlian Decoction for Post-TACE Embolization Syndrome in Hepatocellular Carcinoma Patients with the Syndrome of Damp-Heat and Stasis-Toxin[J]. Journal of Nanjing University of traditional Chinese Medicine, 2022, 38(5): 397-403. doi: 10.14148/j.issn.1672-0482.2022.0397
shu

Clinical Observation of Gegen Qinlian Decoction for Post-TACE Embolization Syndrome in Hepatocellular Carcinoma Patients with the Syndrome of Damp-Heat and Stasis-Toxin

doi: 10.14148/j.issn.1672-0482.2022.0397
  • 1.

    Department of Integrated Traditional and Western Medicine, Jiangsu Cancer Hospital, Nanjing 210009, China

  • 2.

    School of Chinese Medicine, School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China

  • Received Date: 2022-02-13
    Abstract
  •   OBJECTIVE  To observe the efficacy of Gegen Qinlian Decoction on embolization syndrome after transcatheter hepatic arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) patients with the syndrome of damp-heat and stasis-toxin.  METHODS  From January 2019 to December 2021, a total of 100 HCC patients with the syndrome of damp-heat and stasis-toxin in Jiangsu Cancer Hospital were selected and randomly divided into 50 cases in the control group and 50 cases in the treatment group (with 3 cases dropped out). Both groups received TACE treatment, and the control group was treated with conventional western medicine after surgery, while the treatment group was given with Gegen Qinlian Decoction granules based on the treatment in the control group. The course of treatment in both groups was two weeks. The gradation and duration of the main symptoms of post-TACE embolism syndrome were recorded during the treatment period. In addition, the changes in the traditional Chinese medicine (TCM) syndrome score were assessed before and after the treatment. Besides, we measured the liver function indicators [Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Total bilirubin (TB), Gamma-glutamyl transpeptidase (GGT)], lipid metabolism related indexes [Total cholesterol (TC), Triglyceride (TG), Low density lipoprotein cholesterol (LDL-C), High density lipoprotein cholesterol (HDL-C)], as well as the expression levels of immune indexes (relative ratio of CD4+, CD8+, regulatory T cells and CD4+/CD8+), and also performed the morbidity factor correlation analysis.  RESULTS  Within two weeks of treatment, patients in the treatment group had less severe fever, nausea, and vomiting than those in the control group (P < 0.05), and the duration of major symptoms was shorter than that in the control group (P < 0.05). After treatment, the TCM syndromes in both groups alleviated significantly (P < 0.01), but the treatment group had better improvement in fever, nausea, vomiting, poor appetite, and total score than the control group (P < 0.05, P < 0.01). Thus, the efficacy of TCM syndromes was better in the treatment group than in the control group (P < 0.05). On top of that, the liver function, lipid metabolism, and immune-related indexes showed better results in both groups than before treatment (P < 0.05, P < 0.01), while the results relevant to serum ALT, TB, TC, TG and LDL-C were better in the treatment group than in the control group (P < 0.05, P < 0.01). Moreover, the expression levels of peripheral blood CD4+, regulatory T cells, as well as CD4+/CD8+ in the treatment group were lower than those in the control group (P < 0.05, P < 0.01). It is worth noting that TG, LDL-C, TB, ALT levels, and regulatory T-cell ratio were risk factors for the development of major symptoms of III-Ⅳ embolic syndrome (P < 0.05, P < 0.01).  CONCLUSION  Gegen Qinlian Decoction is effective in post-TACE embolization syndrome in HCC patients with the syndrome of damp-heat and stasis-toxin.

     

    • FullText(HTML)
  • loading
    • References(23)
  • [1]
    ZHOU MG, WANG HD, ZENG XY, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204): 1145-1158. doi: 10.1016/S0140-6736(19)30427-1
    [2]
    CHEN WQ, ZHENG RS, BAADE PD, et al. Cancer statistics in China, 2015[J]. CA A Cancer J Clin, 2016, 66(2): 115-132. doi: 10.3322/caac.21338
    [3]
    HARTKE J, JOHNSON M, GHABRIL M. The diagnosis and treatment of hepatocellular carcinoma[J]. Semin Diagn Pathol, 2017, 34(2): 153-159. doi: 10.1053/j.semdp.2016.12.011
    [4]
    XU XF, XING H, HAN J, et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: A multicenter study from China[J]. JAMA Surg, 2019, 154(3): 209-217. doi: 10.1001/jamasurg.2018.4334
    [5]
    XIA LZ, OYANG L, LIN JG, et al. The cancer metabolic reprogramming and immune response[J]. Mol Cancer, 2021, 20: 28. doi: 10.1186/s12943-021-01316-8
    [6]
    SANGINETO M, VILLANI R, CAVALLONE F, et al. Lipid metabolism in development and progression of hepatocellular carcinoma[J]. Cancers, 2020, 12(6): 1419. doi: 10.3390/cancers12061419
    [7]
    中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 中华肝脏病杂志, 2020, 28(2): 112-128. doi: 10.3760/cma.j.issn.1007-3418.2020.02.004

    Department of Medical Administration, National Health and Health Commission of the People's Republic of China. Guidelines for the diagnosis and treatment of primary liver cancer (2019 edition)[J]. Chin J Hepatol, 2020, 28(2): 112-128. doi: 10.3760/cma.j.issn.1007-3418.2020.02.004
    [8]
    刘允怡, 赖俊雄. 肝癌微创介入治疗[J]. 中华肝脏外科手术学电子杂志, 2020, 9(3): 201-205. doi: 10.3877/cma.j.issn.2095-3232.2020.03.001

    LIU YY, LAI JX. Minimally invasive intervention for liver cancer[J]. Chin J Hepatic Surg Electron Ed, 2020, 9(3): 201-205. doi: 10.3877/cma.j.issn.2095-3232.2020.03.001
    [9]
    林晓彤, 张荣杰, 李福阳, 等. 中西医结合治疗原发性肝癌的回顾性研究[J]. 中药材, 2020, 43(5): 1244-1247. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYCA202005040.htm

    LIN XT, ZHANG RJ, LI FY, et al. Retrospective study on the treatment of primary hepatocellular carcinoma by integrated traditional Chinese and western medicine[J]. J Chin Med Mater, 2020, 43(5): 1244-1247. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYCA202005040.htm
    [10]
    王永炎, 鲁兆麟. 中医内科学[M]. 北京: 人民卫生出版社, 2018: 543.

    WANG YY, LU ZL. Internal Medicine of Chinese Medicine[M]. Beijing: People's medical publishing house, 2018: 543.
    [11]
    中山医科大学肿瘤防治中心. 抗癌药急性及亚急性毒性反应分度标准(WHO标准)[J]. 癌症, 1992, 4(3): 254. https://www.cnki.com.cn/Article/CJFDTOTAL-AIZH199203024.htm

    Cancer Center of Zhongshan Medical University. Classification standard for acute and subacute toxicity of anticancer drugs (WHO Standard)[J]. Chin J Cancer, 1992, 4(3): 254. https://www.cnki.com.cn/Article/CJFDTOTAL-AIZH199203024.htm
    [12]
    任娟, 翟笑枫. 原发性肝癌中医证候诊断量表的研制[J]. 中国全科医学, 2018, 21(5): 574-579. doi: 10.3969/j.issn.1007-9572.2017.00.165

    REN J, ZHAI XF. Development of a TCM syndrome-based diagnostic scale for TCM syndrome classification for primary liver cancer[J]. Chin Gen Pract, 2018, 21(5): 574-579. doi: 10.3969/j.issn.1007-9572.2017.00.165
    [13]
    JOHNSTON MP, KHAKOO SI. Immunotherapy for hepatocellular carcinoma: Current and future[J]. World J Gastroenterol, 2019, 25(24): 2977-2989. doi: 10.3748/wjg.v25.i24.2977
    [14]
    LIU XY, WANG ZC, CHEN ZW, et al. Efficacy and safety of transcatheter arterial chemoembolization and transcatheter arterial chemotherapy infusion in hepatocellular carcinoma: A systematic review and meta-analysis[J]. Oncol Res, 2018, 26(2): 231-239. doi: 10.3727/096504017X15051752095738
    [15]
    程紫薇, 程伟, 邢东炜, 等. 中医药治疗肝动脉化疗栓塞术后栓塞综合征进展[J]. 吉林中医药, 2019, 39(11): 1533-1536. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJL201911037.htm

    CHENG ZW, CHENG W, XING DW, et al. Progress in the application of traditional Chinese medicine in the treatment of embolism syndrome after transcatheter arterial chemoembolization[J]. Jilin J Chin Med, 2019, 39(11): 1533-1536. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJL201911037.htm
    [16]
    国家艾滋病和病毒性肝炎等重大传染病防治科技专项"中医药延缓乙型肝炎相关肝癌进展的综合治疗方案研究"课题组, 中国医师协会中西医结合分会肿瘤专业委员会, 河南省康复医学会消化康复分会, 等. 原发性肝癌经肝动脉化疗栓塞术后中西医结合康复专家共识[J]. 临床肝胆病杂志, 2021, 37(7): 1545-1549. doi: 10.3969/j.issn.1001-5256.2021.07.013

    National Science and Technology Major Project of the Ministry of Science and Technology of China-Prevention and Treatment of Major Infectious Diseases such as AIDS and Viral Hepatitis-Research Group of "Comprehensive Treatment Plan for Retarding Hepatitis B Related Liver Cancer Progression with Traditional Chinese Medicine", Oncology Expert Committee of Integrated Traditional Chinese and Western Medicine Branch of Chinese Medical Doctor Association, Digestive Rehabilitation Branch of Henan Rehabilitation Medical Association, et al. Expert consensus on integrated traditional Chinese and Western medicine rehabilitation after transcatheter arterial chemoembolization for primary liver cancer[J]. J Clin Hepatol, 2021, 37(7): 1545-1549. doi: 10.3969/j.issn.1001-5256.2021.07.013
    [17]
    张仲景. 伤寒论[M]. 北京: 人民卫生出版社, 2011: 95.

    ZHANG ZJ. Treatise on Exogenous Febrile Diseases[M]. Beijing: People's medical publishing house, 2011: 95.
    [18]
    ZHAO CZ, WANG B, LIU EY, et al. Correction to: Loss of PTEN expression is associated with PI3K pathway-dependent metabolic reprogramming in hepatocellular carcinoma[J]. Cell Commun Signal, 2021, 19: 52. doi: 10.1186/s12964-021-00745-8
    [19]
    曹盼, 张樱山, 魏学明, 等. 葛根素药理作用研究新进展[J]. 中成药, 2021, 43(8): 2130-2134. doi: 10.3969/j.issn.1001-1528.2021.08.028

    CAO P, ZHANG YS, WEI XM, et al. New progress in pharmacological action of puerarin[J]. Chin Tradit Pat Med, 2021, 43(8): 2130-2134. doi: 10.3969/j.issn.1001-1528.2021.08.028
    [20]
    白庆云, 陶思敏, 谢晶, 等. 黄芩苷对不同类型肝损伤的防治作用及机制的研究进展[J]. 宜春学院学报, 2020, 42(6): 1-4, 10. doi: 10.3969/j.issn.1671-380X.2020.06.001

    BAI QY, TAO SM, XIE J, et al. Review of baicalin on prevention and treatment effects and mechanism of various liver injury[J]. J Yichun Univ, 2020, 42(6): 1-4, 10. doi: 10.3969/j.issn.1671-380X.2020.06.001
    [21]
    宋雷. 基于系统药理及分子对接研究小檗碱对肝细胞癌的作用机制[D]. 广州: 广州中医药大学, 2020.

    SONG L. Exploring the active mechanism of berberine against HCC by systematic pharmacology and molecular docking[D]. Guangzhou: Guangzhou University of Chinese Medicine, 2020.
    [22]
    柴芳妮. 黄连碱抗肝癌及对急性肝损伤保护作用的初步研究[D]. 重庆: 西南大学, 2018.

    CHAI FN. The inhibition of liver cancer and the protection against acute liver failure through coptisine from Coptis chinensis franch[D]. Chongqing: Southwest University, 2018.
    [23]
    王敬, 袁天杰, 陈乐天, 等. 甘草总皂苷及水提物对肝损伤大鼠肠道菌群的影响[J]. 中草药, 2020, 51(1): 101-108. https://www.cnki.com.cn/Article/CJFDTOTAL-ZCYO202001016.htm

    WANG J, YUAN TJ, CHEN LT, et al. Total saponins of Glycyrrhiza inflata and its decoction on intestinal flora in rats with liver injury[J]. Chin Tradit Herb Drugs, 2020, 51(1): 101-108. https://www.cnki.com.cn/Article/CJFDTOTAL-ZCYO202001016.htm
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(8)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (161) PDF downloads(14) Cited by()
    Proportional views
    Related

    Copyright © Journal of Nanjing University of traditional Chinese Medicine

    Sponsored by：Nanjing University of traditional Chinese MedicineAddress：No.138 xianlin Avenue, Qixia District, Nanjing cityChina Pos：210023

    Tel：025-85811935Email：xb@njucm.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return